NexImmune is a clinical-stage biotech company developing therapies for cancer and immune-mediated diseases. Its proprietary technology platform, Artificial Immune Modulation, is used to develop T cell immunotherapies. The company's product candidates include NEXI-001, NEXI-002, and NEXI-003, which are in various stages of clinical trials. NexImmune was founded in 2011 and is based in Maryland.